Examkin

Question

Difficulty: EasyPediatric Hematology and Oncology

A 6-year-old boy is newly diagnosed with Burkitt lymphoma. He presents with a large abdominal mass, and laboratory studies reveal a significantly elevated serum lactate dehydrogenase (LDH) and uric acid level. The oncology team is preparing to begin his treatment but must first address his high risk for developing tumor lysis syndrome (TLS). Arrange the following management steps in the most appropriate sequential order, starting from the most critical initial preventive measure to the intervention reserved for severe, refractory complications.

  1. 1Initiate aggressive intravenous hydration without added potassium.
  2. 2Administer a prophylactic hypouricemic agent (e.g., rasburicase).
  3. 3Administer induction cytotoxic chemotherapy.
  4. 4Initiate renal replacement therapy (e.g., hemodialysis).

Answer

The correct sequence is to first initiate aggressive intravenous hydration, followed by administering a hypouricemic agent, then administering cytotoxic chemotherapy, and finally initiating renal replacement therapy only if severe refractory complications arise.
Tumor lysis syndrome (TLS) is an oncologic emergency caused by the massive release of intracellular contents (potassium, phosphate, and nucleic acids) into the systemic circulation following tumor cell death. In high-risk pediatric patients, such as those with Burkitt lymphoma, prevention is paramount and must follow a specific sequence. The most critical initial step is aggressive intravenous hydration (without potassium) to maintain high urine output and clear metabolites. This is followed by administering a hypouricemic agent (such as rasburicase or allopurinol) to lower uric acid levels. Only after these preventive measures are actively working should cytotoxic chemotherapy be initiated, as it will trigger further rapid cell death. Finally, renal replacement therapy (hemodialysis) is not a preventive measure but a rescue therapy reserved as a last resort for severe complications, such as refractory hyperkalemia or acute renal failure, that do not respond to medical management.

Step-by-Step Solution

1
Identify the patient's risk profile for tumor lysis syndrome (TLS).
The patient has Burkitt lymphoma with a large tumor burden and elevated LDH, indicating a very high risk for TLS.
Risk stratification determines the necessity and intensity of prophylactic measures before starting oncologic treatment.
2
Establish the correct sequence of preventive measures prior to cellular breakdown.
Intravenous hydration and hypouricemic agents (like rasburicase) must be administered first.
These interventions optimize renal clearance and actively lower circulating uric acid levels before chemotherapy induces massive cell lysis.
3
Determine the appropriate timing for chemotherapy and rescue therapies.
Chemotherapy follows prophylaxis; hemodialysis is reserved for refractory cases.
Chemotherapy triggers the lysis and should not be given until the kidneys are protected. Dialysis is only indicated if prophylaxis fails and life-threatening metabolic derangements (e.g., hyperkalemia) occur.

Key Concept

Prevention and management sequence for Tumor Lysis Syndrome in high-risk pediatric malignancies
Rate this question

Topics

Pediatric Hematology and Oncology

More questions from this topic